Al-Shafey, A., Eltebi, D., Ammar, I., Alnadar, M. (2018). Evaluation of Oral Anti-HCV Therapy (OAT) Effects on Serum Lipids Profile in Diabetic Patients. The Egyptian Journal of Hospital Medicine, 73(8), 7231-7236. doi: 10.21608/ejhm.2018.17795
Abdou Mabrouk Al-Shafey; Diaa Mohammad Eltebi; Islam Abdel-Mawla Ammar; Mohamad Ali Alnadar. "Evaluation of Oral Anti-HCV Therapy (OAT) Effects on Serum Lipids Profile in Diabetic Patients". The Egyptian Journal of Hospital Medicine, 73, 8, 2018, 7231-7236. doi: 10.21608/ejhm.2018.17795
Al-Shafey, A., Eltebi, D., Ammar, I., Alnadar, M. (2018). 'Evaluation of Oral Anti-HCV Therapy (OAT) Effects on Serum Lipids Profile in Diabetic Patients', The Egyptian Journal of Hospital Medicine, 73(8), pp. 7231-7236. doi: 10.21608/ejhm.2018.17795
Al-Shafey, A., Eltebi, D., Ammar, I., Alnadar, M. Evaluation of Oral Anti-HCV Therapy (OAT) Effects on Serum Lipids Profile in Diabetic Patients. The Egyptian Journal of Hospital Medicine, 2018; 73(8): 7231-7236. doi: 10.21608/ejhm.2018.17795
Evaluation of Oral Anti-HCV Therapy (OAT) Effects on Serum Lipids Profile in Diabetic Patients
Department of Tropical Medicine, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Abstract
to down regulation of cholesterol level. Interferon (INF) therapy has been shown to decrease cholesterol even further during treatment .With the availability of direct acting antiviral agents (DAAs) the effect of suppressing HCV on lipid metabolism warrantes re-evaluation. Aim of the work : goal of our study was evaluation the changes in lipid profile after treatment of chronic HCV infection with oral antiviral medications in diabetic patients. Methods: this prospective study conducted on 90 HCV infected patients, all patients received Sofosbuvir (SOF) & Daclatasvir (DCV) as a dual therapy for 3 months. They were divided according to the presence or absence of diabetes mellitus (DM) and hyperlipidemia into three main groups; Group I: included 30 diabetic hyperlipidemic patients, Group II: included 30 non-diabetic hyperlipidemic patients, Group III: included 30 non-diabetic non- dyslipidemia patients.Changes of lipid profile on treatment with DAAs were assessed by checking fasting lipid profile at base line, then at end of treatment, and finally 3 months after treatment. Results: there was a statistically significant increase in total cholesterol level (TCHOL) which was maintained after the end of therapy. Changes in TCHOL were driven by changes in low-density lipo-protein (LDL) cholesterol, whereas high-density lipo-protien (HDL) cholesterol and very low-density lipo-protein (VLDL) cholesterol showed no significant changes. There were also no significant changes in tryglyceride (TG) level on treatment. Conclusion: eliminating HCV with DAAs increased TCHOL but had no effect on TG level.
View on SCiNiTO
Top